Literature DB >> 16827214

International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future.

Robert B Nussenblatt1, Chi-Chao Chan, Wyndham H Wilson, Jacob Hochman, Michael Gottesman.   

Abstract

PURPOSE: To bring together multidisciplinary experts to discuss primary central nervous system lymphoma (PCNSL) and primary intraocular lymphoma (PIOL).
METHODS: NIH campus workshop discussion focusing on future work in both clinical and basic lymphoma research.
RESULTS: The discussion lead to recommendations on elucidating disease pathobiology, improving diagnostic accuracy and sensitivity, and novel therapeutic strategies.
CONCLUSIONS: Approaches which have been successfully applied to other neoplasms, such as microarray, may be applied to improve diagnostic accuracy and sensitivity of PCNSL and PIOL and should be systematically incorporated into clinical trials of both. Development of animal models of PCNSL and PIOL may be useful in understanding the unique ocular and CNS milieu. Disease detection by radiological, nuclear medicine, molecular and flow cytometric approaches should be systematically studied to improve early diagnosis, accurate staging, and response evaluation. Improved therapy remains the ultimate goal. Efforts in these arenas should be coordinated on a national and international level.

Entities:  

Mesh:

Year:  2006        PMID: 16827214      PMCID: PMC2518223          DOI: 10.1080/09273940600630170

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  34 in total

1.  Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.

Authors:  Holger Schulz; Hendrik Pels; Ingo Schmidt-Wolf; Ulrich Zeelen; Ulrich Germing; Andreas Engert
Journal:  Haematologica       Date:  2004-06       Impact factor: 9.941

2.  Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas.

Authors:  W H Wilson; J Teruya-Feldstein; T Fest; C Harris; S M Steinberg; E S Jaffe; M Raffeld
Journal:  Blood       Date:  1997-01-15       Impact factor: 22.113

Review 3.  Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.

Authors:  H Pels; H Schulz; U Schlegel; A Engert
Journal:  Onkologie       Date:  2003-08

4.  Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.

Authors:  Hendrik Pels; Ingo G H Schmidt-Wolf; Axel Glasmacher; Holger Schulz; Andreas Engert; Volker Diehl; Anton Zellner; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Marlies Vogt-Schaden; Gerlinde Egerer; Udo Bode; Carlo Schaller; Martina Deckert; Rolf Fimmers; Christoph Helmstaedter; Aslihan Atasoy; Thomas Klockgether; Uwe Schlegel
Journal:  J Clin Oncol       Date:  2003-11-03       Impact factor: 44.544

Review 5.  Primary brain tumours in adults.

Authors:  Anthony Behin; Khe Hoang-Xuan; Antoine F Carpentier; Jean-Yves Delattre
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

Review 6.  Intraocular lymphoma: update on diagnosis and management.

Authors:  Chi-Chao Chan; Dana J Wallace
Journal:  Cancer Control       Date:  2004 Sep-Oct       Impact factor: 3.302

7.  Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment.

Authors:  Adília Hormigo; Lauren Abrey; Murk-Hein Heinemann; Lisa M DeAngelis
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

8.  Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.

Authors:  Eric T Wong; Roy Tishler; Loretta Barron; Julian K Wu
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

9.  The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen.

Authors:  P Moreton; G J Morgan; D Gilson; G M Smith; B A McVerry; J M Davies; M J Mackie; S Bolam; S S Jalihal; M R Howard; L A Parapia; A T Williams; J A Child
Journal:  Cancer Chemother Pharmacol       Date:  2003-12-24       Impact factor: 3.333

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  8 in total

1.  Ocular imaging in primary retinal lymphoma.

Authors:  Chi-Chao Chan; Theodor C Sauer
Journal:  Am J Ophthalmol       Date:  2009-05       Impact factor: 5.258

2.  Subretinal lymphomatous infiltration in primary intraocular lymphoma revealed by optical coherence tomography.

Authors:  Feng Liang; Pierre Olivier Barale; Khé Hoang Xuan; Michel Paques; José-Alain Sahel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-21       Impact factor: 3.117

3.  The future of primary intraocular lymphoma (retinal lymphoma).

Authors:  Chi-Chao Chan; Sylvain Fisson; Bahram Bodaghi
Journal:  Ocul Immunol Inflamm       Date:  2009 Nov-Dec       Impact factor: 3.070

4.  Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.

Authors:  S A Grimm; C A McCannel; A M P Omuro; A J M Ferreri; J-Y Blay; E A Neuwelt; T Siegal; T Batchelor; K Jahnke; T N Shenkier; A J Hall; F Graus; U Herrlinger; D Schiff; J Raizer; J Rubenstein; N Laperriere; E Thiel; N Doolittle; F M Iwamoto; L E Abrey
Journal:  Neurology       Date:  2008-10-21       Impact factor: 9.910

5.  Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients.

Authors:  Xian Zhou; Xianjin Zhou; Huimin Shi; Jie Lai; Qingping Wang; Yi Li; Kun Chen; Qingjian Li; Qiang Zhou; Xia Cao; Bobin Chen; Jianjiang Xiao
Journal:  BMC Ophthalmol       Date:  2020-05-12       Impact factor: 2.209

6.  A case of primary intraocular lymphoma treated by intravitreal methotrexate.

Authors:  Eunah Kim; Changhyun Kim; Jiwoong Lee; Youngwook Cho
Journal:  Korean J Ophthalmol       Date:  2009-09-08

7.  Case 01-2017 - Primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016.

Authors:  Yujuan Wang; Dik S Cheung; Chi-Chao Chan
Journal:  Ann Eye Sci       Date:  2017-07-01

8.  The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper.

Authors:  Justine R Smith; Alexandra L Farrall; Janet L Davis; Joke H de Boer; Anthony J Hall; Manabu Mochizuki; H Nida Sen; Hiroshi Takase; Ninette H Ten Dam-van Loon; Valérie Touitou; Daniel V Vasconcelos-Santos; David J Wilson; Steven Yeh; Mark H B Radford
Journal:  BMJ Open       Date:  2022-07-28       Impact factor: 3.006

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.